```
009535334
```

WPI Acc No: 1993-228874/199329

Treatment of rheumatoid arthritis - using azauridine cpds., e.g.

azaribine or 6-azauridine

Patent Assignee: UR LABS INC (URUR-N); UR LAB INC (URUR-N)

Inventor: DRELL W

Number of Countries: 021 Number of Patents: 006

Patent Family:

	•						
Patent No	Kind	Date	Applicat No	Kind	Date	Week	
EP 552057	Al	19930721	EP 93300267	Α	19930115	199329	В
AU 9331832	A	19930722	AU 9331832	A	19930115	199336	
CA 2087147	A	19930718	CA 2087147	A	19930112	199341	
JP 5345723	Α	19931227	JP 935610	A	19930118	199405	
US 5389617	Α	19950214	US 92822630	Α	19920117	199512	
			US 93152255	A	19931112		
AU 661364	В	19950720	AU 9331832	A	19930115	199537	

Priority Applications (No Type Date): US 92822630 A 19920117

Cited Patents: 6.Jnl.Ref; CA 1211375; US 5023083

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

EP 552057 A1 E 7 A61K-031/70

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

JP 5345723 A 3 A61K-031/505

US 5389617 A 3 A61K-031/70 Cont of application US 92822630 AU 661364 B A61K-031/70 Previous Publ. patent AU 9331832

AU 9331832 A A61K-031/70 CA 2087147 A A61K-031/53

Abstract (Basic): EP 552057 A

The use of an azauridine cpd. for the treatment of rheumatoid arthritis is new. The cpd. is administered at 10--50~mg/kg/day for an initial period to reduce the adverse effects and then at above 50~mg/kg/day to relieve the rheumatoid arthritis.

Pref. the azauridine (pref. azaribine or 6-azauridine) is initially administered at 15-35 mg/kg/day for 1-4 weeks, at 50-100 mg/kg/day in the second period for 4-8 weeks and then at above 100 mg/kg/day for as long as the patient shows improvement. A pyrixoxine cpd. may also be administered (pref. at least 0.0005 moles/mole of azauridine).

USE/ADVANTAGE - Azaribine is an effective oral treatment for psoriasis, psoriatic arthritis, mycosis fungoides, herpes simplex and small pox. At higher doses azaribine has anti-inflammatory activity bu shows severe side effects (e.g. fever, joint pain, joint swelling, edema, nausea, emesis, exanthema, painful and rigid muscles and depression). The novel regime avoids these side effects. The erythrocyte sedimentation rate is reduced, the joint tenderness/pain index is improved, the join/swelling index is improved and the patients have a feeling of well being. The azaribine is pref. administered orally in a formulation which avoids absorption through the stomach and which contains a pyridoxal phosphate cpd. (pref. pyridoxine hydrochloride) pref. at above 0.025 mole/mole azaribine (to avoid pyridoxal phosphate deficiency). Administriation of 6-azauridine has to be done i.v. to avoid metabolism by intestinal bacteria to 6-azauracil which is toxic

Dwg.0/0

1

Abstract (Equivalent): US 5389617 A

Treating rheumatoid arthritis comprises: (a) admin. of 10-50 mg/kg/day azauridine (AZ) cpd. and at least 0.0005 moles pyridoxine (PY) per mole AZ, for a period to reduce the adverse side effects associated with admin. of AZ cpds. at dosage levels of at least 50 mg/kg/day; and then (b) admin. of a higher dose level of at least 50 mg/kg/day AZ cpd. and at least 0.005 moles PY per mole AZ, to show improvement in rheumatoid arthritis.

Pref. the first period is 1-4 weeks using 15-35 mg/kg/day AZ cpd. and the second is 4-8 weeks, using at least 100 mg/kg/day AZ cpd.

The AZ cpd. is azaribine or 6-azauridine. Admin. is esp. by i.v. infusion or is oral, AZ being encapsulated in an enteric coating.

USE/ADVANTAGE - Admin. of AZ cpd. reduces erythrocyte sedimentation rate, improves joint tenderness/pain index, joint swelling index and feeling of well being. The method does not have the adverse side effects associated with prior art.

Dwg.0/0

Derwent Class: B03

International Patent Class (Main): A61K-031/505; A61K-031/53; A61K-031/70

International Patent Class (Additional): A61K-009/08; A61K-009/28;

A61K-031/44

009342661

WPI Acc No: 1993-036125/199304

Oral compsn. contg. therapeutic protein, esp. allergen or antigen stabilised by inactive protein and coated with enteric polymer, used as vaccines and to treat allergies

Patent Assignee: UNIV CINCINNATI (UYCI-N)

Inventor: MICHAEL J G; LITWIN A

Number of Countries: 037 Number of Patents: 010

Pat	ent Family:							/	
	ent No	Kind	Date	App	licat No	Kind	Date	Week	
	9300077	A1	19930107		92US5004	Α	19920611	199304	В
	9222496	Α	19930125	UΑ	9222496	A	19920611	199319	
	590060	A1	19940406	ΕP	92914240	Α	1,9920611	199414	
				WO	92US5004	A ,	1 9920611		
JP.	6508371	W	19940922	WO	92055004	A	19920611	199442	
0.	00000.2			JP	93501524	A	19920611		
EP	590060	A4	19940525	ΕP	92914240	Α.		199531	
ΔU	664561	В	19951123	ΑU	9222496	Α	19920611	199603	
	590060	B1	19970917	ΕP	92914240	Α	19920611	199742	
5.	33000			WO	921255004	Α	19920611		
DE	69222306	E	19971023	DE	£22306	A	19920611	199748	
-	0,7222300	_			92914240	Α	19920611		
				MO		Α	19920611		
ES	2109362	Т3	1998011	EP	92914240	Α	19920611	199810	
	6174529	B1	20010116	US	91719160	A	19910621	200106	
05	0174323			US	92994932	Α	19921222		
				US	94178503	Α	19940107		
				US	94329685	A	19941026		
		A		US	95472711	Α	19950605		
					97947551	A	19971011		

Priority Applications (No Type Date): US 91719160 A 19910621; US 92994932 A 19921/22; US 94178503 A 19940107; US 94329685 A 19941026; US 95472711 A 1995/0605; US 97947551 A 19971011